G1 Therapeutics Inc (GTHX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
G1 Therapeutics (GTHX) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.14 per share a year ago.
Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
G1 Therapeutics (NASDAQ: GTHX ) stock is rocketing higher on Wednesday after the company announced an acquisition deal with Pharmacosmos Group. Pharmacosmos Group has agreed to acquire all outstanding shares of GTHX stock for $7.15 in cash.
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
While small-capitalization biotechnology firms bring much potential to the table, they also represent a source of unpredictability. Nevertheless, for risk-takers, oncology specialist G1 Therapeutics (NASDAQ: GTHX ) appears quite enticing.
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
Biotechnology stocks can be thrilling and profitable when you're on the winning side of a trade. G1 Therapeutics' (NASDAQ: GTHX ) started hot, but then the bottom fell out after an unfortunate announcement.
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
G1 Therapeutics, Inc. faces a setback as a trial for triple-negative breast cancer fails to improve survival, leading to a significant market selloff. The company's main drug, trilaciclib, shows potential for reducing severe neutropenia but fails to meet the primary endpoint in the breast cancer trial. Despite financial challenges and market pessimism, G1 Therapeutics maintains an approved drug with growing sales and potential in niche markets like small cell lung cancer.
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
Shares of G1 Therapeutics Inc GTHX are trading lower after the company released topline results from the final OS analysis of its Phase 3 PRESERVE 2 trial evaluating the efficacy and safety of trilaciclib administered before chemotherapy (gemcitabine and carboplatin; GCb) for metastatic Metastatic Triple Negative Breast Cancer (TNBC).
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
G1 Therapeutics (NASDAQ: GTHX ) stock is falling hard on Monday after the company provided investors with an update on its Phase 3 clinical trial of trilaciclib as a breast cancer treatment. G1 Therapeutics notes that this trial failed to meet its primary endpoint.
G1 Therapeutics' breast cancer drug fails in late-stage trial
G1 Therapeutics said on Monday its drug for a rare, aggressive form of breast cancer did not meet the main goal of overall survival in a late-stage trial.
